11 completed, 4 unknown, 1 recruiting. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 11, Unknown 4, Recruiting 1 |
Follow Mumps: new trials by email Literature Review of Mumps trials Research Report on Mumps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients Commercial measles, mumps, and rubella (MMR) vaccine - Heart Transplant Infection Prevention | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 60 | 2025-09-11 | 2026-09-24 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV) - Mumps, Influenza | Phase 4 | Unknown | Sinovac Biotech Co., Ltd | 400 | 2023-11-04 | 2024-01-17 |
| Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine, Inactivated SARS-CoV-2 vaccine coadministered with MMR, Inactivated SARS-CoV-2 vaccine administered alone - SARS-CoV-2 Infection, Varicella | Phase 4 | Unknown | Shanghai Municipal Center for Disease Control and Prevention | 540 | 2023-08-01 | 2023-07-19 |
| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m） - Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 300 | 2021-08-25 | 2022-03-29 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine Mumps vaccine, measles, mumps and rubella combined vaccine, live - Mumps | Phase 4 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 920 | 2020-11-18 | 2021-08-18 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine - Encephalitis, Japanese, Measles | Phase 4 | Completed | PATH | 628 | 2016-10-13 | 2020-10-14 |
| Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Measles, mumps and rubella Combined Vaccine, Live - Measles, Mumps | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 873 | 2016-03-01 | 2017-05-19 |
| Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Combined measles-mumps-rubella (MMR) vaccine - PRIORIX® - Measles, Rubella | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 14 | 2015-02-04 | 2026-03-30 |
| Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients MMR vaccination - Measles | Phase 4 | Unknown | Klara M. Pósfay Barbe | 90 | 2013-04-01 | 2020-09-18 |
| Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations MMR Vaccine - Measles, Mumps | Phase 4 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 240 | 2012-10-01 | 2016-07-11 |
| Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) VAQTA®, ProQuad - Hepatitis A, Measles | Phase 4 | Completed | Merck Sharp & Dohme LLC | 1800 | 2007-03-26 | 2019-02-04 |
| Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine - Measles, Mumps | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 470 | 2006-09-01 | 2014-01-22 |
| Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Measles, Mumps, Rubella and Chickenpox (live vaccine) - Mumps, Rubella | Phase 4 | Completed | GlaxoSmithKline | 1439 | 2005-05-01 | 2016-09-21 |
| Safety Study of a Refrigerator-stable Formulation of VARIVAX® VARIVAX®, M-M-RTM II - Varicella, Measles | Phase 4 | Completed | Merck Sharp & Dohme LLC | 500 | 2004-12-01 | 2017-03-14 |
| Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. MMR vaccine (Priorix) - Rubella, Mumps | Phase 4 | Completed | GlaxoSmithKline | 150 | 2000-11-01 | 2016-09-20 |
Measles (15) · Rubella (14) · Chickenpox (4) · Encephalitis, Japanese (2) · Hepatitis A (2) · COVID-19 (1) · Escherichia coli Infections (1) · Influenza, Human (1)
Infections (16) · Mononegavirales Infections (16) · Mouth Diseases (16) · Paramyxoviridae Infections (16) · Parotid Diseases (16) · Parotitis (16) · RNA Virus Infections (16) · Rubulavirus Infections (16) · Salivary Gland Diseases (16) · Stomatognathic Diseases (16) · Virus Diseases (16) · Morbillivirus Infections (15) · Rubivirus Infections (14) · Togaviridae Infections (14) · DNA Virus Infections (4)
Measles-Mumps-Rubella Vaccine (5) · Mumps Vaccine (2) · Chickenpox Vaccine (1) · Hepatitis A Vaccines (1) · Influenza Vaccines (1) · Long-Term Synaptic Depression (1) · Vaccines (1) · Vaccines, Attenuated (1) · measles, mumps, rubella, varicella vaccine (1)
GlaxoSmithKline (2) · Merck Sharp & Dohme LLC (2) · Assistance Publique - Hôpitaux de Paris (1) · Centers for Disease Control and Prevention, China (1) · Children's Mercy Hospital Kansas City (1) · Klara M. Pósfay Barbe (1) · Liaoning Chengda Biotechnology CO., LTD (1) · PATH (1) · Sanofi Pasteur, a Sanofi Company (1) · Shanghai Municipal Center for Disease Control and Prevention (1) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (1) · Sinovac Biotech Co., Ltd (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1) · Zhejiang Provincial Center for Disease Control and Prevention (1)
China (6) · France (2) · Brazil (1) · Finland (1) · Germany (1) · Greece (1) · Italy (1) · Philippines (1) · Poland (1) · Switzerland (1) · Turkey (Türkiye) (1) · United States (1)
Huanyu Wang (1) · Jiang Wu (1) · Klara M Posfay-Barbe, MD, MS (1) · Lirong Huang, Bachelor (1) · Maria Rosario Capeding, MD (1) · Odile Launay, MD, PhD (1) · Victoria Blazek, PharmD, BCPPS (1) · Weijun Hu, Master (1) · Zhuoying Huang (1)
2014 (1)